The study did not meet the primary endpoint, showing no difference in OS, although efficacy data suggest a positive trend for continued bevacizumab plus standard of care (SOC) beyond progression compared with SOC alone [ 25 ].
1
—
—
The study did not meet the primary endpoint, showing no difference in OS, although efficacy data suggest a positive trend for continued bevacizumab plus standard of care (SOC) beyond progression compared with SOC alone [ 25 ].